XTL Biopharmaceuticals Ltd. logo
XTL Biopharmaceuticals Ltd. XTLB
$ 1.9 2.7%

Annual report 2022
added 11-23-2024

report update icon

XTL Biopharmaceuticals Ltd. Balance Sheet 2011-2024 | XTLB

Annual Balance Sheet XTL Biopharmaceuticals Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - - -3.29 M -2.02 M -3.82 M -2.16 M -2.89 M -3.31 M -123 K

Long Term Debt

- - - - - - - - - - - -

Long Term Debt Current

- - - - - - - - - - - -

Total Non Current Liabilities

- - - - - 2.67 M - - - 11 K 13 K -

Total Current Liabilities

- - - - - - - - - - - -

Total Liabilities

- - 254 K 232 K 253 K 2.97 M 330 K 436 K 965 K 1.23 M 11.1 M 629 K

Deferred Revenue

- - - - - - - - - 35 K - -

Retained Earnings

- - -155 M -154 M -153 M -156 M -155 M -152 M -148 M -146 M -144 M -143 M

Total Assets

4.19 M 6.62 M 6.5 M 7.21 M 8.58 M 6.59 M 3.02 M 5.32 M 5.64 M 8.02 M 11.1 M 4.07 M

Cash and Cash Equivalents

2.09 M 2.97 M 3.63 M 4.46 M 3.26 M 3.29 M 2.02 M 3.82 M - - - -

Book Value

- 6.62 M 6.25 M 6.98 M 8.32 M 3.62 M 2.69 M 4.89 M 4.68 M 6.78 M - 3.44 M

Total Shareholders Equity

- - 3.61 M 6.52 M 7.27 M 3.62 M 2.69 M 4.89 M - - - -

All numbers in USD currency

Quarterly Balance Sheet XTL Biopharmaceuticals Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -155 M - -156 M - -156 M - - - -153 M - - - -153 M - - - -156 M - - - -155 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 6.62 M - 6.95 M - 6.5 M - - - 7.21 M - - - 8.58 M - - - 6.59 M - - - 3.02 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 2.97 M - 2.92 M - 3.63 M - 4.03 M - 4.46 M - - - 3.26 M - - - 3.29 M - - - 2.02 M - - - 3.82 M - - - 2.16 M - - - - - - - - - - - - - - -

Book Value

- - - - 6.62 M - 6.95 M - 6.5 M - - - 7.21 M - - - 8.58 M - - - 6.59 M - - - 3.02 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 5.33 M - 3.28 M 4.37 M 3.61 M - 5.6 M 6.71 M 6.52 M - - - 7.27 M - - - 3.62 M - - - 2.69 M - - - 4.89 M - - - 4.68 M - - - - - - - - - - - - - - -

All numbers in USD currency